Table 3. Chronic Health Conditions and Percent Associated with Cancer-Related Therapy.

Potential Late Effect	Screening test	Criteria for positive screeninga	Exposure Groups	Number	n	Prevalence		Attributable fractionb,c
						(%)	95% CI	(%)	95% CI
Cardiovascular Risk Factors
Hypertension	Blood pressure	BP > 140/90	Total	1713	387	(22.6)	[20.6-24.7]	(9.3)	[−16.3-29.2]
			Exposed	1508	342	(22.7)	[20.6-24.9]
			Unexposed	205	45	(22.0)	[16.5-28.3]
Dyslipidemia	Fasting lipid panel	Total cholesterol ≥ 200	Total	1713	872	(50.9)	[48.5-53.3]	(15.5)	[10.2-20.5]
		mg/dL, or triglycerides ≥	Exposed	807	491	(60.8)	[57.4-64.2]
		150 mg/dL, or LDL ≥ 130 mg/dL or HDL < 40 mg/dL	Unexposed	906	381	(42.1)	[38.8-45.3]
Obese	Body mass index	BMI> 30.0 kg/m2	Total	1713	624	(36.5)	[34.1-38.8]	(42.1)	[34.4-48.9]
	(BMI)		Exposed	714	345	(48.3)	[44.6-52.1]
			Unexposed	999	279	(27.9)	[25.2-30.8]
Cardiac
Arrhythmia	Electrocardiogram	Detection of rhythm	Total	1713	126	(7.4)	[6.2-8.7]	(−17.8)	[−68.4-17.7]
		abnormality	Exposed	1214	85	(7.0)	[5.6-8.6]
			Unexposed	499	41	(8.2)	[6.0-11.0]
Conduction	Electrocardiogram	Detection of conduction	Total	1713	243	(14.2)	[12.6-15.9]	(−4.3)	[−33.9-18.8]
disorder		abnormality	Exposed	1214	169	(14.0)	[12.0-16.0]
			Unexposed	499	74	(14.8)	[11.8-18.3]
History of cardiac	Electrocardiogram	ECG abnormality	Total	1713	387	(5.7)	[20.6-24.7]	(57.1)	[36.4-71.0]
ischemia		indicating history of	Exposed	501	48	(9.6)	[7.2-12.5]
		ischemia	Unexposed	1212	49	(4.1)	[3.0-5.3]
Endocrine/Reproductive
Hypogonadotropic	Menstrual history,	Amenorrhea before 40	Total	830	34	(4.1)	[2.9-5.7]	(90.7)	[83.2-94.9]
hypogonadism	Follicle stimulating	years and estradiol	Exposed	65	20	(30.8)	[19.9-43.5]
(females)d	hormone (FSH),	below normal range and	Unexposed	765	14	(1.8)	[1.0-3.1]
	Estradiol	FSH within or below normal range
Hypogonadotropic	Luteinizing	Testosterone below	Total	832	55	(6.5)	[5.1-8.5]	(88.4)	[80.1-93.3]
hypogonadism	hormone (LH),	normal range and LH	Exposed	88	23	(26.2)	[17.3-36.6]
(males)e	Morning testosterone	within or below normal range	Unexposed	744	32	(4.3)	[3.0-6.0]
Central	Thyroid stimulating	Free T4 below normal	Total	1674	78	(4.7)	[3.7-5.8]		[89.2-98.9]
hypothyroidismf	hormone (TSH),	range and TSH within or						(96.6)
	Free T4	below normal range	Exposed	152	38	(25.0)	[18.3-32.7]
			Unexposed	1522	40	(2.7)	[1.9-3.6]
Diabetes mellitus	Fasting serum	Fasting glucose ≥ 126	Total	1713	101	(5.9)	[4.8-7.1]	(41.7)	[12.2-61.3]
	glucose	mg/dL or hemoglobin ≥	Exposed	714	56	(7.8)	[6.0-10.1]
	hemoglobin A1C	A1C 6.4%	Unexposed	999	45	(4.5)	[3.3-6.0]
Primary	TSH, Free T4	Free T4 below normal	Total	1674	128	(7.7)	[6.4-9.0]	(97.0)	[90.6-99.0]
hypothyroidismf		range and TSH above	Exposed	910	125	(13.8)	[11.6-16.2]
		normal range	Unexposed	764	3	(0.4)	[0.1-1.1]
Primary ovarian failure	Menstrual history,	Amenorrhea before age	Total	830	65	(7.8)	[6.1-9.9]	(100.0)
	Follicle stimulating	< 40 years and FSH	Exposed	553	65	(11.8)	[9.2-14.7]
	hormone (FSH),Estradiol	above normal range	Unexposed	277	0	(0.0)
Leydig cell failured	Morning	Testosterone below	Total	832	71	(8.5)	[6.7-10.6]	(96.5)	[91.2-98.6]
	testosterone, LH	normal range and LH	Exposed	574	66	(11.5)	[9.0-14.4]
		above normal range	Unexposed	258	5	(2.0)	[0.6-4.5]
Hematology
Abnormal blood	Complete blood	Abnormal blood counts	Total	1713	49	(2.9)	[2.1-3.8]	(5.6)	[−96.8-54.8]
counts	count with	consistent with	Exposed	1375	40	(3.0)	[2.1-3.9]
	differential	cytopenia, myelodysplasia, myeloproliferative disorder	Unexposed	338	9	(2.7)	[1.2-5.0]
Hepatic
Hepatopathy	Alanine	ALT, AST, bilirubin	Total	1713	205	(12.0)	[10.5-13.6]	(14.5)	[−10.7-33.9]
	aminotransferase	above reference range	Exposed	920	119	(13.0)	[10.8-15.3]
	(ALT), aspartate aminotransferase (AST), bilirubin		Unexposed	793	86	(10.9)	[8.8-13.2]
Neurosensory
Neuropathy	Modified total	Score on mTNS 4+	Total	1713	348	(20.4)	[18.4-22.3]	(42.3)	[20.6-58.1]
	neuropathy scale		Exposed	1422	312	(21.9)	[19.8-34.2]
	(mTNS)		Unexposed	291	36	(12.4)	[8.8-16.7]
Urinary tract
Kidney dysfunction	Urinalysis	Serum creatinine > 1.5	Total	1713	76	(4.5)	[3.5-5.5]	(65.7)	[21.7-85.0]
	BUN, Creatinine	mg/dL	Exposed	1410	71	(5.0)	[4.0-6.3]
	Na, K, Cl, CO2, Ca,	eGFR < 90	Unexposed	303	5	(1.6)	[0.5-3.8]
	Mg, PO4	mL/min/1.73m2 ± Abnormal urinalysis (e.g., proteinuria) ± Electrolyte alterations
Hemorrhagic	Urinalysis	Hematuria	Total	1713	15	(0.9)	[0.5-1.4]	(−128.6)	[−534.0-17.6]
cystitis			Exposed	1130	7	(0.7)	[0.3-1.3]
(microscopic hematuria)			Unexposed	583	8	(1.4)	[0.6-2.7]

^aSee supplemental Table 3 “Criteria for Defining Late Effects” for detailed information about the definitions for positive screening for specific late effects.

^bAttributable fraction indicates the percentage of cases in the cohort that are related to the specific treatment exposure, where A_e% = $\frac{R_e-R_o}{R_g}$ ×100%.

A_e%=Attributable fraction, R_e=absolute risk in exposed, R_o==absolute risk in unexposed.

^cNegative values indicate that the risk for that chronic condition was less in the group that received the treatment exposure than in the group that did not receive the treatment exposure.

^dResults presented for evaluation of hypogonadotropic hypogonadism and primary ovarian failure exclude 50 women with bilateral oophorectomy.

^eResults presented for evaluation of Leydig cell failure exclude 1 man with bilateral orchiectomy.

^fResults presented for evaluation of central and primary hypothyroidism exclude 39 patients with prior thyroidectomy.

Table summarizes prevalence of chronic health conditions detected by comprehensive screening with the core battery of evaluations administered to all study participants.